We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


  Gold Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App

Bio-Rad Showcases Best-in-Class COVID-19 Solutions at AACC 2021

By LabMedica International staff writers
Posted on 27 Sep 2021
Print article
Image: Reliance SARS-CoV-2 RT-PCR Assay Kit (Photo courtesy of Bio-Rad Laboratories, Inc.)
Image: Reliance SARS-CoV-2 RT-PCR Assay Kit (Photo courtesy of Bio-Rad Laboratories, Inc.)

Bio-Rad Laboratories (Hercules, CA, USA) showcased its best-in-class COVID-19 solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest laboratory medicine tradeshow.

At AACC 2021, Bio-Rad exhibited its wide range of products for use in the support of COVID-19 diagnostic screening, confirmation of test results, surveillance, and therapy/vaccine research and development. From molecular testing using real-time PCR or Droplet Digital PCR, to immunology assays, the company highlighted its wide range of solutions that provide best in class sensitivity and accuracy. Bio-Rad’s comprehensive range of products for COVID-19 diagnosis, confirmation, and antibody detection included real-time PCR, droplet digital PCR, and serological testing. The company’s SARS-CoV-2 testing solutions spanning the full course of the viral infection, with options from active infection testing to post-infection antibody testing, were displayed at the event. On display were Bio-Rad’s two COVID-19 RT-PCR molecular in vitro diagnostic tests to detect SARS-CoV-2 under EUA – the Reliance SARS-CoV-2/Flu A/Flu B RT-PCR Assay Kit that detects and differentiates Flu A and Flu B from COVID-19 by targeting nucleocapsid Flu A M1 and Flu B NS2 genes; and Reliance SARS-CoV-2 RT-PCR Assay Kit that detects COVID-19 by targeting nucleocapsid N1 and N2 genes.

Bio-Rad exhibited its COVID-19 ddPCR molecular test – the SARS-CoV-2 ddPCR Kit which is a partition-based endpoint RT-PCR test for the qualitative detection of nucleic acids from SARS-CoV-2 in nasopharyngeal anterior nasal and mid-turbinate nasal swab specimens and nasopharyngeal wash/aspirate plus nasal aspirate specimens from patients suspected of being infected with COVID-19 by a healthcare provider. The company also presented its COVID-19 serology test – the Platelia SARS-CoV-2 Total Ab Assay that detects total anti-nucleocapsid antibodies (IgM, IgA, and IgG) to SARS-CoV-2 in human serum and plasma to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

Additionally, Bio-Rad highlighted its serology solutions for clinical laboratories seeking to detect total anti-nucleocapsid antibodies IgM, IgA, and IgG on an automated or manual immunoassay testing system (Platelia SARS-CoV-2 Total Ab) or use VIROTROL and VIROCLEAR SARS-CoV-2 antibody controls to ensure an unbiased independent assessment of your serology testing systems. Also, the company demonstrated how wastewater testing can be used to detect SARS-CoV-2 viral RNA shed in the stool of symptomatic and asymptomatic infected individuals, providing near real-time surveillance of SARS-CoV-2 viral spread at the community level. The company exhibited several solutions to address the needs of scientists studying COVID-19 such as its Droplet digital PCR that is ideal for detecting SARS-CoV-2 in wastewater. Multiplex immunoassays measure anti-SARS-CoV-2 IgG antibodies in a population. Both the company’s real-time PCR and ddPCR can monitor the variant sequences of SARS-CoV-2 in the population. Also on display at AACC 2021 were Bio-Rad’s solutions to support coronavirus characterization, immune response studies, as well as vaccine and therapeutic development and manufacturing.

Related Links:
Bio-Rad Laboratories

Gold Supplier
Reliance SARS-CoV-2 RT-PCR Assay Kit
Automated Culture Media Preparator
Automatic Biochemistry Analyzer
Falcon 260
Urine Analyzer
ComboStik R-50

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.